The Goldman Sachs Group Boosts Enliven Therapeutics (NASDAQ:ELVN) Price Target to $67.00

Enliven Therapeutics (NASDAQ:ELVN) had its price target hoisted by The Goldman Sachs Group from $59.00 to $67.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 26.77% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. Guggenheim started coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price objective for the company. Mizuho upped their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. HC Wainwright raised their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $70.50.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $52.85 on Tuesday. The company has a market cap of $3.22 billion, a price-to-earnings ratio of -31.65 and a beta of 0.24. The stock’s fifty day moving average price is $45.06 and its 200 day moving average price is $36.90. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $54.88.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Research analysts expect that Enliven Therapeutics will post -1.57 earnings per share for the current year.

Insider Activity

In related news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares in the company, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 26,018 shares of company stock valued at $1,113,888. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. Tema ETFs LLC increased its holdings in shares of Enliven Therapeutics by 41.0% during the 2nd quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after purchasing an additional 17,638 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in Enliven Therapeutics during the second quarter worth $878,000. FNY Investment Advisers LLC purchased a new stake in Enliven Therapeutics during the second quarter worth $126,000. Assenagon Asset Management S.A. acquired a new stake in Enliven Therapeutics during the second quarter valued at $15,559,000. Finally, Seven Fleet Capital Management LP grew its position in Enliven Therapeutics by 159.4% during the first quarter. Seven Fleet Capital Management LP now owns 259,283 shares of the company’s stock valued at $10,164,000 after buying an additional 159,330 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.